[go: up one dir, main page]

MX2009009188A - Metodo para aliviar los efectos secundarios de la terapia de acido retinoico y/o mejorar la eficacia sin interferir con la eficacia. - Google Patents

Metodo para aliviar los efectos secundarios de la terapia de acido retinoico y/o mejorar la eficacia sin interferir con la eficacia.

Info

Publication number
MX2009009188A
MX2009009188A MX2009009188A MX2009009188A MX2009009188A MX 2009009188 A MX2009009188 A MX 2009009188A MX 2009009188 A MX2009009188 A MX 2009009188A MX 2009009188 A MX2009009188 A MX 2009009188A MX 2009009188 A MX2009009188 A MX 2009009188A
Authority
MX
Mexico
Prior art keywords
efficacy
side effects
retinoic acid
interfering
acid therapy
Prior art date
Application number
MX2009009188A
Other languages
English (en)
Inventor
Myron K Jacobson
Elaine L Jacobson
Russell Coyle
Hyuntae Kim
Donna L Coyle
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Publication of MX2009009188A publication Critical patent/MX2009009188A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • A61K2800/884—Sequential application

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

La invención se relacione al uso de ésteres alquílicos de ácido nicotínico, especialmente nicotinato de miristilo, para inhibir los efectos secundarios asociados con la terapia de ácido retinoico. También una parte de la invención es un método para mejorar la diferenciación de célula de la piel al administrar el éster alquílico de ácido nicotínico en una cantidad suficiente para incrementar la expresión de caspasa 14 y filagrina. Las deficiencias en la expresión de estas moléculas se pueden tratar de esta manera también.
MX2009009188A 2007-02-28 2008-02-27 Metodo para aliviar los efectos secundarios de la terapia de acido retinoico y/o mejorar la eficacia sin interferir con la eficacia. MX2009009188A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90393707P 2007-02-28 2007-02-28
PCT/US2008/002605 WO2008106177A2 (en) 2007-02-28 2008-02-27 Method for alleviating side effects of retinoic acid therapy and/or improving efficacy without interfering with efficacy

Publications (1)

Publication Number Publication Date
MX2009009188A true MX2009009188A (es) 2010-03-26

Family

ID=39721805

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009188A MX2009009188A (es) 2007-02-28 2008-02-27 Metodo para aliviar los efectos secundarios de la terapia de acido retinoico y/o mejorar la eficacia sin interferir con la eficacia.

Country Status (15)

Country Link
US (1) US9642845B2 (es)
EP (1) EP2120917B1 (es)
JP (1) JP5699414B2 (es)
CN (1) CN101742916B (es)
AU (1) AU2008219633B2 (es)
CA (1) CA2679315C (es)
DK (1) DK2120917T3 (es)
ES (1) ES2458566T3 (es)
IL (1) IL200598A (es)
MX (1) MX2009009188A (es)
NZ (1) NZ579416A (es)
PL (1) PL2120917T3 (es)
PT (1) PT2120917E (es)
RU (2) RU2442577C2 (es)
WO (1) WO2008106177A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383167B2 (en) 2011-03-08 2013-02-26 Elc Management, Llc Method for cosmetically treating caspase-14 deficiency
FR2975002B1 (fr) * 2011-05-12 2020-08-14 Jean-Noel Thorel Procede de traitement cosmetique de la peau en deux etapes successives
US10076479B1 (en) 2018-05-08 2018-09-18 Avon Products, Inc. Methods for treating skin
US9956151B2 (en) * 2015-03-05 2018-05-01 Avon Products, Inc. Methods for treating skin
EP4146158A1 (en) * 2020-05-06 2023-03-15 Mary Kay, Inc. Cosmetic composition comprising gluconolactone and glycolic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5939082A (en) * 1995-11-06 1999-08-17 The Procter & Gamble Company Methods of regulating skin appearance with vitamin B3 compound
CA2352964C (en) * 1998-12-01 2006-10-17 University Of Kentucky Research Foundation A method for enhancing protective cellular responses to genotoxic stress in skin
DE60134002D1 (de) * 2000-04-14 2008-06-26 Niadyne Corp Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie
MXPA03007609A (es) * 2001-02-27 2004-06-30 Univ Michigan Uso de inhibidores egfr naturales para evitar efectos secundarios debidos a terapia de retinoide, jabones y otros estimulos que activan el receptor del factor de crecimiento epidermico.
DE60229041D1 (de) * 2001-03-08 2008-11-06 Univ Kentucky Res Found Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen
EP1901817A2 (en) * 2005-07-08 2008-03-26 The Procter and Gamble Company Personal care compositions and methods for the beautification of mammalian skin and hair

Also Published As

Publication number Publication date
RU2442577C2 (ru) 2012-02-20
CN101742916B (zh) 2015-08-19
WO2008106177A2 (en) 2008-09-04
IL200598A (en) 2015-07-30
IL200598A0 (en) 2010-05-17
RU2010128725A (ru) 2012-01-20
PL2120917T3 (pl) 2014-09-30
CA2679315C (en) 2013-06-25
AU2008219633B2 (en) 2011-05-26
RU2463046C2 (ru) 2012-10-10
US20100173957A1 (en) 2010-07-08
JP5699414B2 (ja) 2015-04-08
EP2120917A2 (en) 2009-11-25
HK1143955A1 (zh) 2011-01-21
EP2120917A4 (en) 2011-09-14
PT2120917E (pt) 2014-04-24
EP2120917B1 (en) 2014-01-22
CN101742916A (zh) 2010-06-16
DK2120917T3 (da) 2014-04-07
ES2458566T3 (es) 2014-05-06
RU2009135872A (ru) 2011-04-10
JP2010520202A (ja) 2010-06-10
CA2679315A1 (en) 2008-09-04
US9642845B2 (en) 2017-05-09
AU2008219633A1 (en) 2008-09-04
WO2008106177A3 (en) 2008-11-06
NZ579416A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
AU2016202421B2 (en) Method of treating neurological conditions with cardiac glycosides
MX2010004074A (es) Combinacion 059.
PH12018501410A1 (en) Therapeutically active compounds and their method of use
PH12015501336A1 (en) Personal cleansing compositions containing zinc amino acid/trimethylglycine halide
PT1365762E (pt) Processo para aumentar os níveis de leptina utilizando compostos do ácido nicotínico
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
MD4371B1 (ro) Derivaţi de benzo¢f]¢1,4]oxazepin-5-one ca modulatori ai canalelor ionice
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
NZ600874A (en) Fluorinated derivatives of deferiprone
PH12012000176A1 (en) Zinc oxide/acid containing compositions and methods for treating and/or preventing enzymatic irritation
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
MX2009009188A (es) Metodo para aliviar los efectos secundarios de la terapia de acido retinoico y/o mejorar la eficacia sin interferir con la eficacia.
MX345675B (es) Metodo para tratar condiciones neurologicas con extracto de especie nerium o especie thevetia.
MX352904B (es) Compuestos de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo.
MX336436B (es) Uso de danazol para el tratamiento de nefropatía diabética.
MX2009008846A (es) Dispositivo de seguridad.
MX2008000838A (es) Composiciones y metodos para tratar infeccion bacteriana gram positiva en un sujeto mamifero.
WO2012020989A3 (ko) 니코틴산 아데닌 디뉴클레오티드 인산 또는 그의 유도체를 포함하는 약학적 또는 화장료 조성물
AU2016204146A1 (en) Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid
PH12015501561A1 (en) Method of treatment of diseases
WO2008042892A3 (en) Fatty acid amide hydrolase inhibitors for energy metabolism disorders
WO2012044963A3 (en) Perfluorocarbons for use in treating pruritus
MX2010007527A (es) Composicion farmaceutica, uso del derivado 2-iminopirrolidina para la produccion de la composicion farmaceutica y kit para el tratamiento o mejora de enfermedaes cardiacas.
TW200833352A (en) Composition for treating a cerebrovascular disease and a method for increasing expression of erythropoietin

Legal Events

Date Code Title Description
FG Grant or registration